STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
STAT
FEBRUARY 5, 2024
But the planned purchase probably tells us something larger about how the pharmaceutical industry manufactures drugs, a topic that might seem dry and academic but that has had an impact on everything from sales of GLP-1 medicines to the ability of companies to make vaccines during the pandemic.
Let's personalize your content